年仅57岁知名大学女教授去世，与多位名人一样皆因这种凶险的肿瘤

Core Viewpoint - The article discusses the recent passing of Professor Zhang Jing, a prominent figure in the field of life sciences, due to cholangiocarcinoma, highlighting the aggressive nature of this cancer and the challenges in early detection and treatment [3][4][5]. Group 1: Cholangiocarcinoma Overview - Cholangiocarcinoma, also known as bile duct cancer, is a highly heterogeneous and aggressive disease, accounting for only 3% of gastrointestinal malignancies, but its incidence is notably higher in Asian countries compared to Western nations [5][6]. - The disease has a poor prognosis, and surgical intervention is the only curative option for early-stage cholangiocarcinoma [6]. Group 2: Early Detection Challenges - Early symptoms of cholangiocarcinoma are often subtle, with only about 10% of patients being diagnosed at a stage where surgical removal of the tumor is possible [6]. - Known risk factors include primary sclerosing cholangitis, intrahepatic bile duct stones, congenital bile duct cysts, and liver cirrhosis, but many patients lack identifiable risk factors, complicating early detection efforts [6]. Group 3: Recent Advances in Treatment - Recent breakthroughs in cholangiocarcinoma treatment have been reported, including a novel therapeutic regimen called "three-drug four-drug golp" (gemox chemotherapy + Levatinib + PD-1 monoclonal antibody Tislelizumab), which has filled an international gap in treatment options for inoperable cholangiocarcinoma patients [7].